https://revivapharma.com/reviva-pharmaceuticals-announces-positive-safety-data-from-drug-drug-interaction-clinical-study-of-brilaroxazine/
Reviva announces it passed a required safety study for brilaroxazine
3 Likes
Thank you! From Wikipedia:
In August, 2022, Reviva Pharmaceuticals, the manufacturer of brilaroxazine, announced successful enrollment of approximately one fifth of study participants for a phase III clinical trial of the drug. The study, which includes clinical sites in the United States, Europe and Asia, aims to assess the efficacy of this agent in the treatment of schizophrenia. An anticipated study completion date in March 2023 is anticipated.
1 Like